CHILL-SHibernation-Like Therapy Safety and Efficacy in Acute Ischemic Stroke Patients Undergoing Reperfusion Therapy

This clinical study focuses on the safety and preliminary effectiveness of a unique treatment approach, called Hibernation-Like Therapy, for patients who have experienced an acute ischemic stroke (AIS) and are eligible for reperfusion therapy. This treatment combines two medications, Chlorpromazine and Promethazine (C+P), and is designed to help protect the brain during stroke. The study is important as it aims to find a new way to improve care for stroke patients, potentially reducing damage caused by the stroke and improving recovery. The study is divided into two parts: a dose-escalation phase and a dose-expansion phase. In the dose-escalation phase, the doses of Chlorpromazine and Promethazine will be gradually increased to find the safest and most effective dose. Participants will receive the study drugs through an intravenous infusion, followed by reperfusion therapy. The safety of the treatment will be closely monitored for 3 days after administration. In the dose-expansion phase, more participants will receive the determined safe and effective dose of the study drugs. Throughout the study, participants will undergo ECG monitoring, vital sign checks, and imaging follow-ups to evaluate the safety and effectiveness of the treatment.